Original article

Effectiveness of postoperative transarterial chemoembolization for huge intrahepatic cholangiocarcinoma

Expand
  • 1a. Department of Medical Oncology, 1b. Department of General Surgery, General Hospital of Eastern Theater Command, PLA, Jiangsu Nanjing 210002, China
    2. Hepatopancreatobiliary Center, Zhongda Hospital, Southeast University, Jiangsu Nanjing 210009, China
    3. Department of Hepatic Surgery Ⅵ, Eastern Hepatobiliary Surgery Hospital, Navy Medical University, Shanghai 200433, China

Received date: 2021-01-21

  Online published: 2022-07-27

Abstract

Objective To investigate the effect of postoperative transarterial chemoembolization (TACE) for huge intrahepatic cholangiocarcinoma (ICC). Methods Data of 125 huge ICC (diameter ≥10 cm) patients with surgical treatment treated with or without TACE (TACE group 35 cases, and non-TACE group 90 cases) between January 2009 and December 2013 were analyzed retrospectively. Both recurrence rate and overall survival (OS) rate were analyzed using the Kaplan-Meier method and the difference using Log-Rank test. Cox regression analysis was used to explore the independent risk factors of postoperative recurrence and OS. Propensity score matching was used to reduce the difference between groups. Subgroup analysis was done for benefited patients from TACE based on the 8th TNM staging of ICC. Results TACE group had similar recurrence and OS with non-TACE group. 5-year recurrence rate and OS rate were 85.7% vs. 84.4%, P=0.487; 22.9% vs. 20.0%, P=0.426, respectively. After 1∶1 propensity score matching with 33 cases each group, there was no significant difference between two groups (P=0.114 for recurrence, P=0.197 for OS). According to TNM sta-ging, there were 61 cases in stage Ⅰ and 64 cases in stage Ⅱ. Staging analysis showed that TACE group and non-TACE groups yielded similar recurrence and OS in patients with stage Ⅰ. However, for patients in stage Ⅱ, TACE group had lower recurrence rate (91.7% vs. 97.5%, P=0.022) and higher OS rate (12.5% vs. 2.5%, P=0.002). After adjustment for multiple tumors, vascular invasion, and CEA ≥5 μg/L, TACE was independent risk factor of recurrence (hazard ratio: 0.564, 95%CI: 0.327-0.974) and OS (hazard ratio: 0.449, 95%CI: 0.259-0.777) in patients with stage Ⅱ. Conclusions For patients with huge ICC, postoperative TACE may improve the prognosis of patients with TNM stage Ⅱ.

Cite this article

SI Anfeng, LEI Zhengqing, YANG Pinghua, JIANG Tao, WANG Xuan, CHENG Zhangjun . Effectiveness of postoperative transarterial chemoembolization for huge intrahepatic cholangiocarcinoma[J]. Journal of Surgery Concepts & Practice, 2021 , 26(02) : 138 -143 . DOI: 10.16139/j.1007-9610.2021.02.010

References

[1] Aljiffry M, Abdulelah A, Walsh M, et al. Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature[J]. J Am Coll Surg, 2009, 208(1):134-147.
[2] Wang Y, Li J, Xia Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy[J]. J Clin Oncol, 2013, 31(9):1188-1195.
[3] Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J]. J Hepatol, 2014, 60(6):1268-1289.
[4] Shen WF, Zhong W, Liu Q, et al. Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study[J]. World J Surg, 2011, 35(9):2083-2091.
[5] Wu ZF, Zhang HB, Yang N, et al. Postoperative adjuvant transcatheter arterial chemoembolisation improves survival of intrahepatic cholangiocarcinoma patients with poor prognostic factors: results of a large monocentric series[J]. Eur J Surg Oncol, 2012, 38(7):602-610.
[6] Li T, Qin LX, Zhou J, et al. Staging, prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resection[J]. Liver Int, 2014, 34(6):953-960.
[7] Jeong S, Zheng B, Wang J, et al. Transarterial chemoembolization: a favorable postoperative management to improve prognosis of hepatitis B virus-associated intrahe-patic cholangiocarcinoma after surgical resection[J]. Int J Biol Sci, 2017, 13(10):1234-1241.
[8] Lu Z, Liu S, Yi Y, et al. Serum gamma-glutamyl transferase levels affect the prognosis of patients with intrahepatic cholangiocarcinoma who receive postoperative adjuvant transcatheter arterial chemoembolization: a propensity score matching study[J]. Int J Surg, 2017, 37:24-28.
[9] Li J, Wang Q, Lei Z, et al. Adjuvant transarterial chemoembolization following liver resection for intrahe-patic cholangiocarcinoma based on survival risk stratifica-tion[J]. Oncologist, 2015, 20(6):640-647.
[10] Wang L, Deng M, Ke Q, et al. Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: a multicenter retrospective study[J]. Cancer Med, 2020, 9(8):2674-2685.
[11] Austin PC. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations[J]. Biom J, 2009, 51(1):171-184.
[12] Mazzaferro V, Gorgen A, Roayaie S, et al. Liver resection and transplantation for intrahepatic cholangiocarcinoma[J]. J Hepatol, 2020, 72(2):364-377.
[13] Spolverato G, Kim Y, Alexandrescu S, et al. Is hepatic resection for large or multifocal intrahepatic cholangiocarcinoma justified? results from a multi-institutional colla-boration[J]. Ann Surg Oncol, 2015, 22(7):2218-2225.
[14] Hyder O, Marques H, Pulitano C, et al. A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience[J]. JAMA Surg, 2014, 149(5):432-438.
[15] Sapisochin G, Facciuto M, Rubbia-Brandt L, et al. Liver transplantation for “very early” intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment[J]. Hepatology, 2016, 64(4):1178-1188.
[16] Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives[J]. Gut, 2014, 63(5):844-855.
[17] Wang Z, Ren Z, Chen Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study[J]. Clin Cancer Res, 2018, 24(9):2074-2081.
[18] Wang H, Du PC, Wu MC, et al. Postoperative adjuvant transarterial chemoembolization for multinodular hepatocellular carcinoma within the Barcelona Clinic Liver Cancer early stage and microvascular invasion[J]. Hepatobiliary Surg Nutr, 2018, 7(6):418-428.
[19] Ke Q, Lin N, Deng M, et al. The effect of adjuvant therapy for patients with intrahepatic cholangiocarcinoma after surgical resection: a systematic review and meta-analysis[J]. PLoS One, 2020, 15(2):e0229292.
Outlines

/